New Revision of MDCG 2020-16 Guidance on IVD Classification: Key Updates in Version 4
The Medical Device Coordination Group (MDCG) published Revision 4 of its guidance document MDCG 2020-16, titled "Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation (EU) 2017/746". This updated version provides further clarification on the application of the classification rules outlined in Annex VIII of the IVDR.
MedNet EC-REP
Author
As the European Authorised Representative for many IVD manufacturers, MedNet EC-REP supports its clients in understanding and implementing these regulatory updates. Below, we highlight the main changes introduced in Revision 4 and what they mean for IVD manufacturers placing products on the EU market.
What’s New in Revision 4?
The main changes in this revision concern the SARS-CoV-2 tests. They are now no longer classified in class D, but in class C in the case of self-tests and in class B in the case of tests for professional use. This is reflected in the amended examples for Rule 1 (second indent), Rule 4 and Rule 6.
With this revision, the MDCG continues its effort to improve regulatory clarity and support consistent implementation across the EU. Manufacturers are encouraged to review the updated guidance in detail and assess whether any of their products may be affected by the revised interpretation of classification rules.
Download the full Document: MDCG 2020-16 rev.4
Related Articles
MDCG 2025-10: New PMS Guidance for MDR & IVDR
The MDCG released new PMS guidance in December 2025. Learn what MDCG 2025-10 means for your MDR and IVDR compliance strategy.
EUDAMED’s first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates